Market Assessment, Prostate Cancer U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer Physician & Payer Forum US 2015 Report

The U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer report surveyed 50 medical oncologists, 52 urologists, and 30 MCO pharmacy and medical directors to capture their views on anticipated prescribing, reimbursement, and market access barriers in relation to current and emerging agents in prostate cancer. Five premium-priced therapies—Zytiga (Johnson & Johnson), Xtandi (Medivation), Provenge (Valeant), Xofigo (Bayer), and Jevtana (Sanofi)—are approved in the United States for prostate cancer, driving the metastatic castrate-resistant prostate cancer (mCRPC) market to become increasingly crowded and competitive. As novel therapies aim to enter this market, sequencing of treatments and gaining optimal reimbursement will be of increasing importance.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Prostate Cancer (U.S. Physician and Payer Perspectives on Novel Treatment Options for Prostate Cancer) | Physician & Payer Forum | US | 2015

Related Market Assessment Reports

Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Detailed, Expanded Analysis (US)

Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast

Attention-Deficit-Hyperactivity Disorder – Access & Reimbursement – Detailed, Expanded Analysis (US)

Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)

Bipolar Disorder – Unmet Need – Detailed, Expanded Analysis (US/EU)